The United Kingdom and the United States have secured a major bilateral deal that will ensure no duties on British drug exports entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the National Health Service (NHS). This pledge guarantees that import taxes on these key goods will stay at zero for a timeframe of three years.
This agreement comes after previous threats to significantly raise duties on branded pharmaceutical imports, with potential rates discussed up to double the cost.
"This deal between the United Kingdom strengthens the international landscape for innovative medicines and brings much-needed balance to transatlantic drug exports," a statement declared.
Trade Significance
Medicines are one of the Britain's biggest goods shipped to the America, which is by far the primary buyer for large UK drugmakers.
Export figures show that in the one-year period leading up to September, the UK exported medicines worth over eleven billion pounds to the US. This figure made up a significant portion of British export trade in that period.
"This agreement safeguards work, stimulates funding and sets the stage for the UK to establish itself as a international leader for life sciences," a minister remarked.
Key British Pledges
The agreement includes several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to increase total public funding on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage drug companies must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds were more than 20%.
Recent Tensions
This agreement comes amid a protracted row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
This friction were heightened by assertions that American consumers were charged several times more for the same drugs than people in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been paused or abandoned, while substantial funding commitments have been pledged toward American operations.
A senior figure stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had declined as a percentage of its total funding over the last ten years.
